secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2022-08-23T23:59:59+00:00
Accession:  0001654954-22-011676
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience receives USDA CVB jurisdiction for coccidiosis biologic; new study in Sept 2022
--------------------------------------------------------------------------------

- USDA CVB affirms jurisdiction over novel immune-modulating biologic for coccidiosis in broilers, removing regulatory ambiguity.
- Company continues licensing discussions with a major animal health company for product candidate.
- Strategic partner to begin 42-day in vivo study in September 2022; results expected Q1 2023.
- No financial results or guidance were provided in this corporate update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422011676/0001654954-22-011676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495422011676/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-011676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer